M. F. Hebert, H. E. Smith, T. C. Marbury, S. K. Swan, W. B. Smith, R. W. Townsend, D. Buell, J. Keirns and I. Bekersky, “Pharmacokinetics of Micafungin in Healthy Volunteers, Volunteers with Moderate Liver Disease, and Volunteers with Renal Dysfunction,” Journal of Clinical Pharmacology, Vol. 45, No. 10, 2005, pp. 1145-1152. Hdoi:10.1177/0091270005279580

has been cited by the following article:

• TITLE: Pharmacokinetics of Micafungin in Adult Patients with Invasive Candidiasis and Candidemia

  AUTHORS: Nasrullah A. Undre, Paul Stevenson, Ernst-Rüdiger Kuse, Ignace Demeyer

  KEYWORDS: Micafungin; Pharmacokinetics; Invasive Candidiasis; Candidemia

  JOURNAL NAME: Open Journal of Medical Microbiology, Vol.2 No.3, September 26, 2012

  ABSTRACT: Micafungin is an efficacious and well-tolerated echinocandin with in vitro and in vivo activity against a broad range of Candida species. The objective of this randomized, double-blind study was to examine the pharmacokinetic parameters of micafungin and its metabolites in a subset of adult patients with invasive candidiasis or candidemia. The study was conducted at 27 sites in four countries, including eight in Europe. Micafungin 100 mg/day or liposomal amphotericin B 3 mg/kg/day were administered once daily as a 1-hour infusion in a blinded manner. The minimum duration of therapy was 14 days. To define plasma analyte (micafungin and metabolites) concentration-time profiles, serial blood samples were collected after the first dose (Day 1), and at the end of therapy (EOT). For patients who received treatment for longer than 2 weeks, an additional profile was obtained during Week 2. To determine plasma trough analyte concentrations, blood samples were collected immediately prior to dosing on Day 2, Week 2, and EOT. In 20 evaluable, micafungin-treated patients, plasma micafungin concentrations peaked at completion of the 1-hour infusion and then declined biexponentially. Plasma concentrations of the micafungin metabolites (M-1, M-2, and M-5) remained low (